XVI International AIDS Conference: Part 2.
Boyle
Brian A
BA
Department of International Medicine and Infectious Diseases, New York Presbyterian Hospital-Weill Medical College of Cornell University, New York, USA.
Cohen
Calvin J
CJ
Moyle
Graeme J
GJ
Elion
Richard
R
Sax
Paul E
PE
Frank
Ian
I
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D065100:CCR5 Receptor Antagonists; D002986:Clinical Trials as Topic; D000069454:Darunavir; D006678:HIV; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006801:Humans; D061466:Lopinavir; D009930:Organic Chemicals / Q000627:therapeutic use; D011744:Pyrimidinones / Q000627:therapeutic use; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium; D019713:Receptors, CCR5 / Q000627:therapeutic use; D019438:Ritonavir / Q000627:therapeutic use; D016879:Salvage Therapy; D013449:Sulfonamides / Q000627:therapeutic use
D065100:CCR5 Receptor Antagonists; D017320:HIV Protease Inhibitors; D009930:Organic Chemicals; D011744:Pyrimidinones; D011760:Pyrrolidinones; D019713:Receptors, CCR5; D013449:Sulfonamides; D061466:Lopinavir; D000068898:Raltegravir Potassium; D019438:Ritonavir; D000069454:Darunavir